Overview
TVRD market data
Price History
TVRD price chart · 1M
- O
- 1.81
- H
- 1.83
- L
- 1.81
- C
- 1.83
- Vol
- 513.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $1.81
- Previous Close
- $1.78
- Day High
- $1.83
- Day Low
- $1.81
- 52 Week High
- $5.66
- 52 Week Low
- $1.67
- 7 Day Return
- -1.08%
- 30 Day Return
- -25.15%
- 90 Day Return
- -46.02%
- 1 Year Return
- -40.39%
- Daily Notional Volume
- $938.8 Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$46.60 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.36 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -700.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.50 – $43.65 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $16.6M · P/B 1.93 · P/S 4.66.
Company News
12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga · Aug 18, 2026, 9:06 PM
Tvardi Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.Benzinga · Aug 14, 2026, 2:36 PM
Tvardi Therapeutics Q2 EPS $(0.69) Beats $(0.70) EstimateBenzinga · Aug 14, 2026, 11:07 AM
8-K filing — Tvardi Therapeutics, Inc. (TVRD)SEC EDGAR · Aug 14, 2026, 11:05 AM
Tvardi Therapeutics To Host KOL Webinar On August 19 To Discuss Current Treatment Landscape In Ulcerative Colitis And Persistent Unmet Needs; Event To Feature New Data From Tvardi And Review Of Phase 1 Healthy Volunteer Results Supporting Potential Of TTI-109 In UCBenzinga · Aug 12, 2026, 12:04 PM
BTIG Maintains Buy on Tvardi Therapeutics, Lowers Price Target to $5Benzinga · Jul 30, 2026, 7:04 PM
Tvardi Therapeutics Selects Ulcerative Colitis As Initial Indication For TTI-109, Says Phase 1 Showed Up To 76% Reduction In Th17 Subsets; Trial Planned For 2027Benzinga · Jul 30, 2026, 11:34 AM
Tvardi Therapeutics Increases At-The-Market Offering Program To $9.69M In SharesBenzinga · Jul 17, 2026, 8:35 PM
Why Is Tvardi Therapeutics Stock Falling Thursday?Benzinga · Jul 9, 2026, 1:10 PM
Tvardi Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 79.35%Benzinga · Jul 8, 2026, 7:45 PM